FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039189935> ?p ?o ?g. }

• W2039189935 endingPage "359" @default.
• W2039189935 startingPage "345" @default.
• W2039189935 abstract "Melasma is an acquired hyperpigmentary disorder characterized by dark patches or macules located on the cheeks, forehead, upper lip, chin, and neck. Treatment of melasma involves the use of topical hypopigmenting agents such as hydroquinone, tretinoin, and azelaic acid and its derivatives.The purpose of this study was to assess the efficacy of a formulation containing a combination of trans-4-(aminomethyl) cyclohexanecarboxylic acid/potassium azeloyl diglycinate/niacinamide compared with an emulsion-based control in the treatment of melasma in Thai adults.In this single-center, randomized, double-blind, controlled study, Thai patients with mild to moderate facial melasma (relative melanin value [RMV] in range of 20-120) were randomized for the application of either the test or the emulsion-based (control) product in the morning and before bedtime for 8 weeks. The supplemental sunscreen product with sun protection factor 30 was distributed to all patients. Subjects were assessed for the intensity of their hyperpigmented skin area by measuring the difference in the absolute melanin value between hyperpigmented skin and normal skin (RMV). This parameter was used as a primary outcome of this study. Additionally, the severity of melasma was determined visually using the Melasma Area and Severity Index (MASI) scored independently by 3 investigators. The assessments of melasma intensity and other skin properties were performed before administration (week 0) and every 2 weeks thereafter for up to 8 weeks. Other skin properties, including moisture content, pH, and redness (erythema value), were measured. Adverse events (AEs), including erythema, scaling, and edema, were also assessed by a dermatologist using the visual grading scale of Frosch and Kligman and COLIPA.The resulting primary intent-to-treat (ITT) population included 33 patients in the test group and 34 patients in the control group. Sixty patients completed all 8 weeks of the study (on-treatment [OT] population): 91% (30) of the 33 patients in the test group, and 88% (30) of the 34 patients in the control group. Between-group differences in mean RMV were statistically significant at week 6 in both the primary ITT (P = 0.005) and OT (P = 0.006) populations. The significant differences in mean MASI scores between the test and the control groups were initially observed at weeks 4 (P = 0.005) and 8 (P = 0.027) in the OT and primary ITT populations, respectively. Other parameters, including skin pH, erythema, and moisture content did not significantly change from baseline at any time point of study. The incidence of AEs was not different between the test (4/33 [12%]) and control (5/34 [15%]) groups.The significant differences in RMVs between the test and control groups were observed after 6 weeks of treatment, both in the primary ITT and OT populations. The incidence of patients with AEs was not significantly different between the test and control groups." @default.
• W2039189935 created "2016-06-24" @default.
• W2039189935 creator A5000340826 @default.
• W2039189935 creator A5007006760 @default.
• W2039189935 creator A5047606655 @default.
• W2039189935 creator A5066194062 @default.
• W2039189935 creator A5073974805 @default.
• W2039189935 date "2010-12-01" @default.
• W2039189935 modified "2023-09-28" @default.
• W2039189935 title "Effects of trans-4-(aminomethyl) cyclohexanecarboxylic acid/potassium azeloyl diglycinate/niacinamide topical emulsion in Thai adults with melasma: a single-center, randomized, double-blind, controlled study" @default.
• W2039189935 cites W1964340452 @default.
• W2039189935 cites W1968055097 @default.
• W2039189935 cites W1968843680 @default.
• W2039189935 cites W1990323058 @default.
• W2039189935 cites W2006756180 @default.
• W2039189935 cites W2042842416 @default.
• W2039189935 cites W2060540686 @default.
• W2039189935 cites W2092706340 @default.
• W2039189935 cites W2095289520 @default.
• W2039189935 cites W2099202432 @default.
• W2039189935 cites W2109040608 @default.
• W2039189935 cites W2109709951 @default.
• W2039189935 cites W2122423912 @default.
• W2039189935 cites W2131437788 @default.
• W2039189935 cites W2135571659 @default.
• W2039189935 cites W2135737980 @default.
• W2039189935 cites W2139127377 @default.
• W2039189935 cites W2145682122 @default.
• W2039189935 cites W2149250648 @default.
• W2039189935 cites W2161999508 @default.
• W2039189935 cites W4247295358 @default.
• W2039189935 doi "https://doi.org/10.1016/s0011-393x(10)80001-3" @default.
• W2039189935 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3969619" @default.
• W2039189935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24688154" @default.
• W2039189935 hasPublicationYear "2010" @default.
• W2039189935 type Work @default.
• W2039189935 sameAs 2039189935 @default.
• W2039189935 citedByCount "4" @default.
• W2039189935 countsByYear W20391899352017 @default.
• W2039189935 countsByYear W20391899352021 @default.
• W2039189935 countsByYear W20391899352022 @default.
• W2039189935 crossrefType "journal-article" @default.
• W2039189935 hasAuthorship W2039189935A5000340826 @default.
• W2039189935 hasAuthorship W2039189935A5007006760 @default.
• W2039189935 hasAuthorship W2039189935A5047606655 @default.
• W2039189935 hasAuthorship W2039189935A5066194062 @default.
• W2039189935 hasAuthorship W2039189935A5073974805 @default.
• W2039189935 hasBestOaLocation W20391899351 @default.
• W2039189935 hasConcept C141071460 @default.
• W2039189935 hasConcept C16005928 @default.
• W2039189935 hasConcept C2776677263 @default.
• W2039189935 hasConcept C2779121184 @default.
• W2039189935 hasConcept C2780446394 @default.
• W2039189935 hasConcept C71924100 @default.
• W2039189935 hasConceptScore W2039189935C141071460 @default.
• W2039189935 hasConceptScore W2039189935C16005928 @default.
• W2039189935 hasConceptScore W2039189935C2776677263 @default.
• W2039189935 hasConceptScore W2039189935C2779121184 @default.
• W2039189935 hasConceptScore W2039189935C2780446394 @default.
• W2039189935 hasConceptScore W2039189935C71924100 @default.
• W2039189935 hasIssue "6" @default.
• W2039189935 hasLocation W20391899351 @default.
• W2039189935 hasLocation W20391899352 @default.
• W2039189935 hasLocation W20391899353 @default.
• W2039189935 hasLocation W20391899354 @default.
• W2039189935 hasOpenAccess W2039189935 @default.
• W2039189935 hasPrimaryLocation W20391899351 @default.
• W2039189935 hasRelatedWork W1984222861 @default.
• W2039189935 hasRelatedWork W1998884512 @default.
• W2039189935 hasRelatedWork W204079223 @default.
• W2039189935 hasRelatedWork W2044494528 @default.
• W2039189935 hasRelatedWork W2384432545 @default.
• W2039189935 hasRelatedWork W2585436449 @default.
• W2039189935 hasRelatedWork W2622442578 @default.
• W2039189935 hasRelatedWork W3133801084 @default.
• W2039189935 hasRelatedWork W4239981746 @default.
• W2039189935 hasRelatedWork W4285802715 @default.
• W2039189935 hasVolume "71" @default.
• W2039189935 isParatext "false" @default.
• W2039189935 isRetracted "false" @default.
• W2039189935 magId "2039189935" @default.
• W2039189935 workType "article" @default.